348 related articles for article (PubMed ID: 25324717)
1. Ubiquitin-proteasome system involvement in Huntington's disease.
Ortega Z; Lucas JJ
Front Mol Neurosci; 2014; 7():77. PubMed ID: 25324717
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitin-modifying enzymes in Huntington's disease.
Sap KA; Geijtenbeek KW; Schipper-Krom S; Guler AT; Reits EA
Front Mol Biosci; 2023; 10():1107323. PubMed ID: 36926679
[TBL] [Abstract][Full Text] [Related]
3. Global changes to the ubiquitin system in Huntington's disease.
Bennett EJ; Shaler TA; Woodman B; Ryu KY; Zaitseva TS; Becker CH; Bates GP; Schulman H; Kopito RR
Nature; 2007 Aug; 448(7154):704-8. PubMed ID: 17687326
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain.
Díaz-Hernández M; Valera AG; Morán MA; Gómez-Ramos P; Alvarez-Castelao B; Castaño JG; Hernández F; Lucas JJ
J Neurochem; 2006 Sep; 98(5):1585-96. PubMed ID: 16787406
[TBL] [Abstract][Full Text] [Related]
5. Differential activities of the ubiquitin-proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons.
Tydlacka S; Wang CE; Wang X; Li S; Li XJ
J Neurosci; 2008 Dec; 28(49):13285-95. PubMed ID: 19052220
[TBL] [Abstract][Full Text] [Related]
6. The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model.
van Hagen M; Piebes DGE; de Leeuw WC; Vuist IM; van Roon-Mom WMC; Moerland PD; Verschure PJ
BMC Genomics; 2017 May; 18(1):373. PubMed ID: 28499347
[TBL] [Abstract][Full Text] [Related]
7. Juvenile Huntington's Disease Skin Fibroblasts Respond with Elevated Parkin Level and Increased Proteasome Activity as a Potential Mechanism to Counterbalance the Pathological Consequences of Mutant Huntingtin Protein.
Aladdin A; Király R; Boto P; Regdon Z; Tar K
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31717806
[TBL] [Abstract][Full Text] [Related]
8. The ubiquitin conjugating enzyme Ube2W regulates solubility of the Huntington's disease protein, huntingtin.
Wang B; Zeng L; Merillat SA; Fischer S; Ochaba J; Thompson LM; Barmada SJ; Scaglione KM; Paulson HL
Neurobiol Dis; 2018 Jan; 109(Pt A):127-136. PubMed ID: 28986324
[TBL] [Abstract][Full Text] [Related]
9. The Ubiquitin Receptor ADRM1 Modulates HAP40-Induced Proteasome Activity.
Huang ZN; Her LS
Mol Neurobiol; 2017 Nov; 54(9):7382-7400. PubMed ID: 27815841
[TBL] [Abstract][Full Text] [Related]
10. Dynamic recruitment of active proteasomes into polyglutamine initiated inclusion bodies.
Schipper-Krom S; Juenemann K; Jansen AH; Wiemhoefer A; van den Nieuwendijk R; Smith DL; Hink MA; Bates GP; Overkleeft H; Ovaa H; Reits E
FEBS Lett; 2014 Jan; 588(1):151-9. PubMed ID: 24291262
[TBL] [Abstract][Full Text] [Related]
11. Atypical ubiquitination by E3 ligase WWP1 inhibits the proteasome-mediated degradation of mutant huntingtin.
Lin L; Jin Z; Tan H; Xu Q; Peng T; Li H
Brain Res; 2016 Jul; 1643():103-12. PubMed ID: 27107943
[TBL] [Abstract][Full Text] [Related]
12. Testing the possible inhibition of proteasome by direct interaction with ubiquitylated and aggregated huntingtin.
Valera AG; Díaz-Hernández M; Hernández F; Lucas JJ
Brain Res Bull; 2007 Apr; 72(2-3):121-3. PubMed ID: 17352935
[TBL] [Abstract][Full Text] [Related]
13. Exploding the Repeat Length Paradigm while Exploring Amyloid Toxicity in Huntington's Disease.
Wetzel R
Acc Chem Res; 2020 Oct; 53(10):2347-2357. PubMed ID: 32975927
[TBL] [Abstract][Full Text] [Related]
14. Accumulation of ubiquitin conjugates in a polyglutamine disease model occurs without global ubiquitin/proteasome system impairment.
Maynard CJ; Böttcher C; Ortega Z; Smith R; Florea BI; Díaz-Hernández M; Brundin P; Overkleeft HS; Li JY; Lucas JJ; Dantuma NP
Proc Natl Acad Sci U S A; 2009 Aug; 106(33):13986-91. PubMed ID: 19666572
[TBL] [Abstract][Full Text] [Related]
15. Co-expression Patterns between
Keo A; Aziz NA; Dzyubachyk O; van der Grond J; van Roon-Mom WMC; Lelieveldt BPF; Reinders MJT; Mahfouz A
Front Mol Neurosci; 2017; 10():399. PubMed ID: 29249939
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting the ubiquitin-proteasome system leads to preferential accumulation of toxic N-terminal mutant huntingtin fragments.
Li X; Wang CE; Huang S; Xu X; Li XJ; Li H; Li S
Hum Mol Genet; 2010 Jun; 19(12):2445-55. PubMed ID: 20354076
[TBL] [Abstract][Full Text] [Related]
17. Precise Excision of the CAG Tract from the Huntingtin Gene by Cas9 Nickases.
Dabrowska M; Juzwa W; Krzyzosiak WJ; Olejniczak M
Front Neurosci; 2018; 12():75. PubMed ID: 29535594
[TBL] [Abstract][Full Text] [Related]
18. Multiple clinical features of Huntington's disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration.
Podvin S; Reardon HT; Yin K; Mosier C; Hook V
J Neurol; 2019 Mar; 266(3):551-564. PubMed ID: 29956026
[TBL] [Abstract][Full Text] [Related]
19. A series of N-terminal epitope tagged Hdh knock-in alleles expressing normal and mutant huntingtin: their application to understanding the effect of increasing the length of normal Huntingtin's polyglutamine stretch on CAG140 mouse model pathogenesis.
Zheng S; Ghitani N; Blackburn JS; Liu JP; Zeitlin SO
Mol Brain; 2012 Aug; 5():28. PubMed ID: 22892315
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
